H.C. Wainwright Thinks Kadmon Holdings’ Stock is Going to Recover

By Jason Carr

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kadmon Holdings (NYSE: KDMN) today and set a price target of $25. The company’s shares closed last Friday at $3.38, close to its 52-week low of $2.25.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 9.7% and a 50.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Kadmon Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $25.

Based on Kadmon Holdings’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $5.57 million and GAAP net loss of $17.57 million. In comparison, last year the company earned revenue of $9.66 million and had a GAAP net loss of $32.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.,00F32J-E